Jean-Francois Martini

Company: Pfizer

Job title: Senior Director, Translational Oncology & Lead, Global Product Development

Bio:

Jean-Francois Martini has over 18 years of biotech and pharma industry experience in pharmacology and clinical translational sciences and is an author/coauthor of over 40 scientific publications. He is currently Sr. Director, Translational Oncology, Global Product Development-Oncology and has been at Pfizer, in La Jolla, California, since December 2011. He was previously Sr. Director, Translational Medicine, at Exelixis, So San Francisco, California, where he contributed to the approval of cobimetinib (preclinical in vivo pharmacology, partnered with Genentech) and cabozantinib (first approval in medullary thyroid cancer) and to projects such as the alliance with Sanofi for the PI3K programs and out-licensing of esaxerenone (mineralocorticoid receptor blocker, approved in Japan for the treatment of hypertension) to Daiichi Sankyo. He completed his postdoctoral training at University of California, San Francisco, where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry and Molecular Biology from University of Paris XI, France.

At Pfizer, he currently leads and/or supports the translational strategy for palbociclib (Ibrance) in non-breast cancer tumors (Head and Neck; Pancreatic cancer); the Renal Cell Cancer franchise (sunitinib and axitinib); and lorlatinib (ALK/ROS1 inhibitor) in Lung Cancer. He also leads the cross functional efforts in the area of liquid biopsy/cfDNA analysis (represents Pfizer as part of Blood Profiling Atlas-Cancer; Friends of Cancer Research; etc), heads the translational strategy for the Pfizer sponsored TRANSLATE study (Profiling resistance to anti-cancer therapies) and is the Pfizer board of director for the WIN consortium (WINTHER and SPRING-01 trials).

Seminars:

Session Q+A 11:00 am

Bringing together the perspectives of the session’s expert speakers, this is your chance to challenge viewpoints, ask any pending questions or bring new discussion points key to advancing clinical trial design, execution and clinical utility demonstration. • How can we maximize patient enrolment in large clinical trials? • Exploring strategies to navigate the analysis of…Read more

day: Day Two

Early Monitoring of cfDNA in Lung Cancer: What Can We Learn from the ALK+ NSCLC case? 9:30 am

• Decreased cfDNA dVAF at 6 weeks was associated with response • Deeper decreases in cfDNA dVAF at 6 weeks were associated with more prolonged PFS and OS • Early cfDNA dynamics may predict lorlatinib efficacy in ALK-positive metastatic NSCLCRead more

day: Day Two